Abbott price target raised to $154 from $150 at Bernstein

Bernstein analyst Lee Hambright raised the firm’s price target on Abbott (ABT) to $154 from $150 and keeps an Outperform rating on the shares. After a low point in September 2025, U.S. healthcare stocks have begun to perform better over the past several months, the firm notes. As the market gets more clarity on many of the macro / policy uncertainties that weighed on healthcare stocks during the course of 2025, Bernstein anticipates better days ahead for healthcare stocks in 2026.